Nautilus Biotechnology (NASDAQ:NAUT) Raised to “Strong-Buy” at Roth Capital

Nautilus Biotechnology (NASDAQ:NAUT) was upgraded by stock analysts at Roth Capital to a “strong-buy” rating in a research note issued on Tuesday, Zacks reports.

Several other research firms have also commented on NAUT. Leerink Partners began coverage on shares of Nautilus Biotechnology in a research report on Wednesday, September 9th. They set an “outperform” rating and a $4.00 price target for the company. Weiss Ratings downgraded shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $3.83.

Nautilus Biotechnology Stock Performance

Shares of Nautilus Biotechnology stock opened at $1.37 on Tuesday. Nautilus Biotechnology has a one year low of $0.80 and a one year high of $4.31. The stock has a market cap of $174.33 million, a price-to-earnings ratio of -3.04 and a beta of 0.87. The stock has a 50 day moving average price of $1.02 and a 200-day moving average price of $2.03.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings data on Monday, July 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. The company had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.10 million.

Institutional Investors Weigh In On Nautilus Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC purchased a new stake in shares of Nautilus Biotechnology in the 2nd quarter valued at $63,000. Corient Private Wealth LP lifted its holdings in Nautilus Biotechnology by 43.6% in the second quarter. Corient Private Wealth LP now owns 164,788 shares of the company’s stock valued at $308,000 after acquiring an additional 50,000 shares during the period. TD Waterhouse Canada Inc. boosted its position in Nautilus Biotechnology by 1,500.0% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 16,000 shares of the company’s stock worth $29,000 after purchasing an additional 15,000 shares in the last quarter. AXQ Capital LP acquired a new stake in shares of Nautilus Biotechnology during the 2nd quarter worth approximately $64,000. Finally, Susquehanna International Group LLP lifted its stake in shares of Nautilus Biotechnology by 1,710.9% in the 2nd quarter. Susquehanna International Group LLP now owns 890,949 shares of the company’s stock valued at $1,666,000 after purchasing an additional 841,749 shares during the period. Institutional investors and hedge funds own 50.71% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc is a life sciences technology company developing tools for large-scale protein analysis. Its goal is to help researchers study the proteome—the complete set of proteins produced by a biological system—with greater sensitivity, accuracy and throughput than conventional methods.

The company’s core offering is the Nautilus Protein Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software. The platform is designed to identify and quantify large numbers of proteins from biological samples and may support applications in drug discovery, biotechnology research, academic studies and the development of precision medicine.

Nautilus Biotechnology was founded in 2016 and is headquartered in Seattle, Washington.